NASDAQ:QLGN Qualigen Therapeutics (QLGN) Stock Price, News & Analysis $1.38 -0.06 (-4.17%) As of 05/7/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Qualigen Therapeutics Stock (NASDAQ:QLGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Qualigen Therapeutics alerts:Sign Up Key Stats Today's Range$1.36▼$1.4850-Day Range$0.96▼$1.5752-Week Range$1.61▼$8.81Volume25,459 shsAverage Volume1.52 million shsMarket Capitalization$2.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Qualigen Therapeutics, Inc. (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology. Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories. These products support the detection and quantification of biomarkers ranging from infectious disease antigens to tumor-associated proteins. Qualigen’s diagnostic portfolio is sold to reference laboratories, hospital systems and point-of-care facilities across North America, Europe and select markets in Asia. Qualigen BioTherapeutics is focused on developing a pipeline of antibody-based and cell-based immunotherapies targeting both hematologic and solid tumors. Its preclinical programs include monoclonal antibodies directed against validated cancer antigens as well as engineered cell therapies designed to enhance tumor recognition and cytotoxicity. The company applies proprietary protein conjugation and high-throughput screening platforms to advance candidates from lead identification through IND-enabling studies.AI Generated. May Contain Errors. Read More Qualigen Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScoreQLGN MarketRank™: Qualigen Therapeutics scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingQualigen Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageQualigen Therapeutics has received no research coverage in the past 90 days.Read more about Qualigen Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Qualigen Therapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Qualigen Therapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Qualigen Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for QLGN. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQualigen Therapeutics does not currently pay a dividend.Dividend GrowthQualigen Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Qualigen Therapeutics this week, compared to 1 article on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Qualigen Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.80% of the stock of Qualigen Therapeutics is held by insiders.Percentage Held by Institutions3.18% of the stock of Qualigen Therapeutics is held by institutions.Read more about Qualigen Therapeutics' insider trading history. Receive QLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Qualigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QLGN Stock News HeadlinesQualigen Therapeutics (NASDAQ:QLGN) Trading Down 4.7% - Time to Sell?May 6 at 2:38 AM | americanbankingnews.comQualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19December 13, 2025 | cnn.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 8 at 1:00 AM | Profits Run (Ad)Qualigen Therapeutics Rebrands to AIxCrypto HoldingsNovember 17, 2025 | msn.comQualigen Therapeutics stockholders approve all proposals with majority voteNovember 17, 2025 | msn.comFaraday Future Becomes Majority Shareholder in Qualigen Therapeutics, Preparing for Corporate Rebranding and Strategic Transformation on November 20November 16, 2025 | quiverquant.comQQualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 StrategyNovember 16, 2025 | globenewswire.comQualigen Therapeutics to rebrand as AIxCryptoOctober 28, 2025 | msn.comSee More Headlines QLGN Stock Analysis - Frequently Asked Questions How have QLGN shares performed this year? Qualigen Therapeutics' stock was trading at $2.34 on January 1st, 2026. Since then, QLGN stock has decreased by 41.0% and is now trading at $1.38. How were Qualigen Therapeutics' earnings last quarter? Qualigen Therapeutics, Inc. (NASDAQ:QLGN) posted its quarterly earnings data on Friday, November, 14th. The company reported ($4.68) earnings per share for the quarter. When did Qualigen Therapeutics' stock split? Qualigen Therapeutics's stock reverse split before market open on Tuesday, November 5th 2024.The 1-50 reverse split was announced on Friday, November 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did Qualigen Therapeutics IPO? Qualigen Therapeutics (QLGN) raised $44 million in an initial public offering (IPO) on Friday, June 19th 2015. The company issued 4,000,000 shares at $10.00-$12.00 per share. How do I buy shares of Qualigen Therapeutics? Shares of QLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Qualigen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Qualigen Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Zomedica (ZOM), Bank of America (BAC), Wells Fargo & Company (WFC), JPMorgan Chase & Co. (JPM) and Abbott Laboratories (ABT). Company Calendar Last Earnings11/14/2025Today5/08/2026Next Earnings (Estimated)5/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QLGN CIK1460702 Webwww.qualigeninc.com Phone(760) 918-9165FaxN/AEmployees50Year Founded1996Profitability EPS (Trailing Twelve Months)($7.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.26 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-202.16% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.12) per share Price / Book-0.33Miscellaneous Outstanding Shares1,695,000Free Float1,664,000Market Cap$2.34 million OptionableNot Optionable Beta0.24 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:QLGN) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...Behind the Markets | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QLGN Stock Alerts